Table 3:

Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on antibody responses to Omicron after three COVID-19 vaccine doses

Variablea	anti-Omicron logio Binding IgGb			anti-Omicron ACE2 % displacementb
	Estimate	95% CI	p-value	Estimate	95% CI	p-value
HIV infection	0.36	0.14 to 0.58	0.0017	3.49	−8.48 to 15.47	0.57
Age (per year)	−0.0030	−0.0078 to 0.0018	0.22	0.21	−0.056 to 0.47	0.12
Male sex	−0.19	−0.36 to −0.017	0.032	−10.26	−19.58 to −0.94	0.031
White ethnicity	0.045	−0.10 to 0.19	0.55	2.05	−6.00 to 10.09	0.62
# Chronic conditions (per additional)	0.0032	−0.083 to 0.090	0.94	−1.27	−5.99 to 3.45	0.60
Dual ChAdOx1 as initial regimen (vs mixed or mRNA)	−0.14	−0.48 to 0.20	0.42	−6.80	−25.39 to 11.80	0.47
mRNA-1273 as third dose (vs BNT162b2)	0.15	0.0074 to 0.30	0.039	5.16	−2.80 to 13.12	0.20
Interval between 1st and 2nd dose (per day)	0.0022	−0.0016 to 0.0059	0.26	−0.044	−0.25 to 0.16	0.67
Interval between 2nd and 3rd dose (per day)	0.0036	0.0012 to 0.0060	0.0039	0.065	−0.067 to 0.20	0.33
Days since 3rd dose	−0.0073	−0.022 to 0.0080	0.35	0.11	−0.72 to 0.94	0.80

^aAnalysis was restricted to participants with no evidence of prior COVID-19

^bBoth immunogenicity measures were quantified in serum using the Meso Scale Diagnostics V-Plex assay (panel 22) which features wild-type and Omicron S-RBD.